The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
|Videos|January 3, 2018
Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy
Author(s)Jesús Berdeja, MD
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
Advertisement
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
The CAR T product bb2121 is for patients with relapsed or refractory multiple myeloma. In a phase I dose-escalation study, 24 patients were collected, and 21 patients were infused with the CAR T cell. Considering that this is a heavily pretreated population, Berdeja says that the number of patients infused was impressive.
Advertisement
Related to this article
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5